|
Wednesday, 21 February 2007 19:56 |
| Company |
Contact |
 |
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
|
 |
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
|
 |
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
|
 |
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
|
 |
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
|
 |
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
|
 |
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
|
 |
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
|
 |
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
|
|
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
|
 |
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
|
 |
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
|
 |
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
|
|
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
|
 |
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
|
 |
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
|
 |
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
|
 |
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
|
|
|
|
Thursday, 10 September 2009 10:45 |
|
CisBio International have just received approval from MHRA for the PENTACIS variation. Please find attached information.
Approval pdf
Summary of product characteristics pdf
|
|
Tuesday, 19 May 2009 15:41 |
|
IBA Molecular UK Ltd are delighted to announce that their Guildford PET radiopharmaceutical facility has been granted a full product licence.
Read article pdf |
|
Thursday, 19 June 2008 15:50 |
IBA FINALIZES ACQUISITION OF CIS BIO INTERNATIONAL BY BUYING OUT THE IRE'S SHARES.
Embargo until 5:40 (Belgian time) – May 29, 2008
Louvain-la-Neuve and Fleurus, Belgium, May 29, 2008 – IBA (Ion Beam Applications S.A.: Reuters IBAB.BR and Bloomberg IBAB.BB) announced today that it has decided to exercise its option topurchase 80.1 percent of the indirect interest held by IRE (Institut National des Radioéléments,Fleurus, Belgium) in CIS bio International (CISBIO).
Read the full press release (pdf) |
|
|
|
|
|
